3 resultados para IMAGING FINDINGS
em AMS Tesi di Dottorato - Alm@DL - Università di Bologna
Resumo:
Aim of the present study was to evaluate the accuracy of transrectal ultrasound biopsy (TRUS-biopsy) directed to regions with abnormal MRI and/or MRSI (magnetic resonance spectroscopic imaging ) for both the transition (TZ) and the peripheral (PZ) zones in patients who presented with persistent suspect for prostate cancer and with prior negative biopsy. We also evaluated relationship between MRSI results and histopathological findings of biopsy. 54 patients with the aforementioned characteristics underwent MRI/MRSI at least 6 months after prior negative biopsy; interval between MRI/3D-MRSI and the further TRUS-biopsy was less than 3 months. The prostate was divided in 12 regions both for imaging interpretation and biopsy. Moreover one to three cores more were taken from each region with abnormal MRI and/or 3D-MRSI. Twenty-two out of 54 patients presented cancer at MRI/MRSI-directed-TRUS-biopsy. On a patient basis the highest accuracy was obtained by assigning malignancy on a positive finding with MRSI and MRI even though it was not significantly greater than that obtained using MRI alone (area under the ROC curve, AUC: 0.723 vs. 0.676). On a region (n=648) basis the best accuracy was also obtained by considering positive both MRSI and MRI for PZ (0.768) and TZ (0.822). Twenty-eight per cent of cores with prostatitis were false positive findings on MRSI, whereas only 2.7% of benign prostatic hyperplasia was false positive. In conclusion the accuracy of MRI/MRSI-directed biopsies in localization of prostate cancer is good in patient and region analyses. The combination of both MRI and MRSI results makes TRUS-biopsy more accurate particularly in the TZ (0.822) for patients with prior negative biopsies. Histopathological analysis showed that the main limitation of MRSI is the percentage of false positive findings due to prostatitis.
Resumo:
Aim: To evaluate the early response to treatment to an antiangiogenetic drug (sorafenib) in a heterotopic murine model of hepatocellular carcinoma (HCC) using ultrasonographic molecular imaging. Material and Methods: the xenographt model was established injecting a suspension of HuH7 cells subcutaneously in 19 nude mice. When tumors reached a mean diameter of 5-10 mm, they were divided in two groups (treatment and vehicle). The treatment group received sorafenib (62 mg/kg) by daily oral gavage for 14 days. Molecular imaging was performed using contrast enhanced ultrasound (CEUS), by injecting into the mouse venous circulation a suspension of VEGFR-2 targeted microbubbles (BR55, kind gift of Bracco Swiss, Geneve, Switzerland). Video clips were acquired for 6 minutes, then microbubbles (MBs) were destroyed by a high mechanical index (MI) impulse, and another minute was recorded to evaluate residual circulating MBs. The US protocol was repeated at day 0,+2,+4,+7, and +14 from the beginning of treatment administration. Video clips were analyzed using a dedicated software (Sonotumor, Bracco Swiss) to quantify the signal of the contrast agent. Time/intensity curves were obtained and the difference of the mean MBs signal before and after high MI impulse (Differential Targeted Enhancement-dTE) was calculated. dTE represents a numeric value in arbitrary units proportional to the amount of bound MBs. At day +14 mice were euthanized and the tumors analyzed for VEGFR-2, pERK, and CD31 tissue levels using western blot analysis. Results: dTE values decreased from day 0 to day +14 both in treatment and vehicle groups, and they were statistically higher in vehicle group than in treatment group at day +2, at day +7, and at day +14. With respect to the degree of tumor volume increase, measured as growth percentage delta (GPD), treatment group was divided in two sub-groups, non-responders (GPD>350%), and responders (GPD<200%). In the same way vehicle group was divided in slow growth group (GPD<400%), and fast growth group (GPD>900%). dTE values at day 0 (immediately before treatment start) were higher in non-responders than in responders group, with statistical difference at day 2. While dTE values were higher in the fast growth group than in the slow growth group only at day 0. A significant positive correlation was found between VEGFR-2 tissue levels and dTE values, confirming that level of BR55 tissue enhancement reflects the amount of tissue VEGF receptor. Conclusions: the present findings show that, at least in murine experimental models, CEUS with BR55 is feasable and appears to be a useful tool in the prediction of tumor growth and response to sorafenib treatment in xenograft HCC.
Resumo:
ABSTRACT Background Cardiac magnetic resonance (CMR) has been shown as promising diagnostic tool in Anderson-Fabry disease (AFD) cardiomyopathy due to its ability to detect fat deposits through lower native T1 values. However no histological validation has been provided to date. Objectives To correlate CMR and histologic findings in different cardiac stages of AFD focusing on T1 mapping. Methods Fifteen AFD patients (49 years [IQR 39-63], 60% females) undergoing CMR (cines, native T1 and T2 mapping, LGE and post-contrast T1 imaging) and endomyocardial biopsy (EMB, n=11) or septal myectomy (n=4), were retrospectively evaluated. Tissue specimens were analyzed with light/electron microscopy and vacuolization amount calculated as percentages of vacuolated myocytes and vacuolated myocyte area (%VMA) through a quantitative histomorphometric color-based analysis. Results In patients without increased indexed left ventricular mass (LVMi) at CMR (67%), T1 fell as %VMA increased (r= -0.883; p<0.001), whereas no clear relationship was evident once increased LVMi occurred (r= -0.501; p=0.389). At least 45% of vacuolized myocytes and 10% of VMA were needed for low T1 to occur. %VMA positively correlate with maximal wall thickness (MWT, r=0.860, p<0.0001) and LVMi (r= 0.762; p<0.001). Increased MWT and LVMi were present with at least 45% and 80% of vacuolated myocytes, respectively, and 18% and 22% of VMA. Conclusions This study demonstrated an inverse correlation between native T1 and the vacuolization amount in patients without increased LVMi at CMR, providing a histological validation of low native T1 in AFD. Importantly, a significant vacuolization burden was needed before low T1 and left ventricle hypertrophy occurred.